In the study of rituximab, lenalidomide, and BTK inhibitor for elderly or unfit patients with DLBCL by Yanan Zhu et al., the top three most prevalent grades 3–4 AEs were neutropenia (25.8%), infection (19.4%), and rash (9.7%) [47]. Here, BTK is linked to diffuse large B-cell lymphoma.